Category: GlaxoSmithKline plc
SetPoint Medical raises $27 million, including contributions from Boston Scientific, Covidien and GlaxoSmithKline's new venture investing arm.
SetPoint Medical said Boston Scientific (NYSE:BSX) and Covidien (NYSE:COV) were among the participants in a $27 million funding round.
A drug/device combination for the treatment of chronic obstructive pulmonary disease co-developed by Theravance and GlaxoSmithKline wins FDA approval.
GI Dynamics lands research partnerships with Medtronic and GlaxoSmithKline, evaluating the relationship between EndoBarrier intestinal liner treatment and patient glucose levels and hormonal changes.
The Murdock Research Institute announces that president Micheal Luther has stepped down.
The David H. Murdock Research Institute expects to name a new leader this summer to succeed president Michael Luther, who has stepped down.
A surprise shakeup at orthopedic device maker Wright Medical Group sees CEO Gary Henley abruptly resign and CTO Frank Bono given his walking papers, with analysts speculating the re-shuffle is due to a U.S. Justice Dept. case that cost the company $8 million last year.
Wright Medical Group Inc. (NSDQ:WMGI) announced a surprise shakeup of its executive team today, firing its chief technology officer and accepting the resignation of CEO Gary Henley.
The Arlington, Tenn.-based maker of orthopedic devices for the foot and ankle market said in a regulatory filing that Henley resigned prior to a board meeting yesterday.
Bedford, Mass.-based Insulet Corp. signs a distribution deal with GlaxoSmithKline plc for the OmniPod insulin system in Canada.
Insulet Corp. (NSDQ:PODD) inked a Canadian distribution deal with GlaxoSmithKline plc (NYSE:GSK) for its OmniPod insulin management system.
The deal gives the British pharma giant — stung by recent problems with its Avandia diabetes drug — exclusive rights to market and sell Bedford, Mass.-based Insulet's OmniPod system north of the border.